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Aims Evidence is accumulating that inﬂammation plays a role in the pathophysiology of heart failure.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) has pro-inﬂammatory properties. We investigated
whether Lp-PLA2 activity is associated with heart failure.
Methods and results Lp-PLA2 activity was determined in a random sample of 1820 subjects from the
Rotterdam Study, a population-based cohort study among persons aged 55 years and over. During a
mean follow-up of 6.7 years, 94 heart failure cases occurred. We excluded participants with heart
failure or coronary heart disease at baseline and we accounted for incident coronary heart disease
during follow-up. We used Cox proportional hazard models to compute hazard ratios adjusted for
age, sex, non-HDL cholesterol, HDL cholesterol, body mass index, systolic blood pressure, diastolic
blood pressure, hypertension, diabetes mellitus, smoking, and C-reactive protein. The hazard ratio
per unit increase of Lp-PLA2 activity was 1.03 [95% conﬁdence interval (95% CI 1.01–1.05]; P for
trend was 0.011. Hazard ratios for the second, third, and fourth quartiles were 1.06 (95% CI
0.55–2.04), 1.43 (95% CI 0.73–2.81), and 2.33 (95% CI 1.21–4.49), respectively, using the lowest quartile
of Lp-PLA2 activity as the reference category.
Conclusion This study suggests that Lp-PLA2 activity is independently associated with incident heart
failure.
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Introduction
During the last 15 years, an interest has developed for the
potential role of inﬂammatory mediators in the pathophy-
siology of heart failure. Associations have been found
between elevated inﬂammatory markers, such as
interleukin-6,
1 tumour necrosis factor-a,
2 and C-reactive
protein,
3 and congestive heart failure. It has been shown
that inﬂammatory mediators may inﬂuence left ventricular
remodelling, left ventricular function, and pulmonary
oedema.
4,5 Furthermore, a correlation has been found
between high blood levels of these inﬂammatory markers
and worsening functional NYHA class, increased hospital-
ization rates, and poorer survival of heart failure patients.
6
Recently, several studies have found an independent associ-
ationbetweentheinﬂammatorymarkerlipoprotein-associated
phospholipase A2 (Lp-PLA2) and risk of coronary heart
disease.
7–11 Lp-PLA2 is an enzyme that circulates in the blood
bound to low-density lipoprotein (LDL) cholesterol. The
enzyme has pro-inﬂammatory properties because of its
capacity to hydrolyse oxidized phospholipids.
12 However, it is
also suggested to have anti-inﬂammatory properties because
of its ability to hydrolyse platelet-activating factor.
13,14 The
relationship found between Lp-PLA2 and coronary heart
disease suggests that the pro-inﬂammatory properties of
Lp-PLA2 outweigh its anti-inﬂammatory properties.
To our knowledge, no studies have yet been conducted on
Lp-PLA2 as a predictor of heart failure. Therefore, we inves-
tigated the association between Lp-PLA2 and risk of heart
failure in the Rotterdam Study, a population-based cohort
study among men and women aged 55 years and over.
Methods
Rotterdam Study
The Rotterdam Study is a population-based cohort study comprising
7983 men and women aged 55 years and over. Its overall aim is to
assess the occurrence of and risk factors for chronic diseases in
the elderly. A detailed description of the objectives and methods
of the Rotterdam Study has been given elsewhere.
15 All residents
of a Rotterdam suburb aged 55 and over were invited to participate
in the study and 78% participated. Baseline measurements started in
1990 and were completed in 1993.
The Medical Ethics Committee of Erasmus Medical Center,
Rotterdam, approved the study. All participants gave written
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 informed consent. This study complies with the Declaration of
Helsinki.
Study population
Lp-PLA2 activity was determined in a random subcohort of 1820 sub-
jects. Prevalent heart failure cases at baseline (n ¼ 47) were
excluded for the current analysis. In addition, 183 subjects were
excluded because they had a history of myocardial infarction, a
history of coronary artery bypass grafting (CABG), or a history of
percutaneous transluminal coronary angioplasty (PTCA) at baseline,
leaving 1590 subjects, who were used for the analysis.
Measurement of Lp-PLA2 activity
Plasma aliquots prepared from non-fasting blood samples were
collected at baseline and stored at 2808C. Lp-PLA2 activity was
measured with a high throughput radiometric activity assay,
as described in detail previously.
11 Lp-PLA2 activity was expressed
as nano moles of platelet-activating factor hydrolysed per minute
per millilitre of plasma samples.
Prior toanalysis ofplasmasamplesfrom theRotterdamStudy,apre-
study validation was conducted to determine the reliability of the
LpPLA2 activity assay. Six plasma samples were tested in triplicate,
and the coefﬁcient of variation (CV) for intra-assay precision ranged
from 3.51–8.96%. To assess inter-assay precision, six plasma samples
were tested on three occasions, and CV ranged from 8.48–15.08%.
Three cycles of freeze–thaw of frozen plasma did not result in
appreciable loss of activity. The assay was therefore considered
suitable for the analysis of the Rotterdam Study samples, which were
tested in duplicate. Samples were re-tested if the replicate CV was
.25%. The range of detection was 8–150 nmol/min per mL.
Measurement of covariates at baseline
At baseline, a trained interviewer visited all participants at home
and collected information using a computerized questionnaire.
The information obtained included current health status, medical
history, drug use, and smoking behaviour. Additionally, established
cardiovascular risk factors were measured at the research centre.
Height and weight were measured, and the body mass index was cal-
culated [weight (kg)/height
2 (m)]. Blood pressure was measured at
the right brachial artery with a random-zero sphygmomanometer,
with the participant seated. We deﬁned hypertension as a systolic
blood pressure  160 mmHg or a diastolic blood pressure
 100 mmHg or the use of blood pressure-lowering medication
with an indication for hypertension.
Non-fasting blood samples were drawn, and total cholesterol and
high-density lipoprotein (HDL) cholesterol were measured within 2
weeks, as described previously.
16 Non-HDL cholesterol was com-
puted by subtracting HDL cholesterol from total cholesterol. LDL
cholesterol was determined in fasting blood samples in 120 ran-
domly selected subjects by use of an enzymatic method (Roche).
We calculated Pearson’s correlation coefﬁcient to compute the cor-
relation of non-HDL cholesterol with LDL cholesterol, r ¼ 0.97,
P , 0.001. We deﬁned diabetes mellitus as a random or post-load
glucose level  11.1 mmol/L or the use of blood glucose-lowering
medication.
17 Using a nephelometric method (Immage, Beckman
Coulter), we measured C-reactive protein in blood samples kept
frozen at 2208C.
A 12-lead resting electrocardiography (ECG) was recorded with an
ACTA electrocardiograph (ESAOTE, Florence, Italy) at a sampling
frequency of 500 Hz and stored digitally. All ECGs were processed
by the modular ECG analysis system (MEANS) to obtain ECG
measurements and interpretations.
18 Myocardial infarction found
on ECG was based on a comprehensive set of criteria that partly
derive from the Minnesota code.
19 A history of myocardial infarction
was considered present in case of a self-report of myocardial infarc-
tion conﬁrmed by ECG or additional clinical information, or the pre-
sence of an ECG characteristic of prior myocardial infarction.
In identifying incident myocardial infarctions (ICD-10 code I21), all
available information, which included ECG, cardiac enzyme levels,
and the clinical judgement of the treating specialist, was used.
Revascularization procedures were identiﬁed by review of hospital
discharge letters from the medical specialist.
Ascertainment of heart failure cases
Assessment of prevalent heart failure at the baseline examination in
the Rotterdam Study has been described elsewhere in detail.
20,21
Brieﬂy, a validated score was used, similar to the deﬁnition of
heart failure of the European Society of Cardiology.
22 This score
was based on the presence of at least two symptoms suggestive of
heart failure (shortness of breath, ankle swelling, and pulmonary
crepitations) or use of medication for the indication of heart
failure, in combination with objective evidence of cardiovascular
disease.
Information on the presence of heart failure at baseline was
obtained for all participants, using one of the following three
methods: interview questions on indication of cardiovascular medi-
cation and breathlessness, linkage of the Rotterdam Study data-
base to a database containing hospital discharge diagnoses from
all hospitals in the Rotterdam area as of 1 January 1991, and
screening of all medical records in retrospect for the occurrence
of heart failure in the majority of participants of the Rotterdam
Study.
For the present study, follow-up started at the baseline examin-
ation, from 1990 till 1993, and was complete until 1 January
2000. Follow-up has been described in detail previously.
21 Brieﬂy,
cases of incident heart failure were obtained by continuously moni-
toring participants of the Rotterdam Study for the occurrence of
heart failure during follow-up through automated linkage with
ﬁles from general practitioners. Each participant’s medical record
was fully screened for incident heart failure. All available data on
these events, such as hospital discharge letters and notes from
general practitioners, were copied from the medical records.
Apart from this systematic follow-up procedure, we used veriﬁed
hospital discharge diagnoses for case ﬁnding, gathered from all hos-
pitals in the Rotterdam area, as described earlier. The diagnosis of
heart failure was classiﬁed as deﬁnite, probable, possible, or
unlikely.
21 Two research physicians independently classiﬁed all
information on potential heart failure events. If there was
disagreement, a consensus was reached in a separate session.
Finally, a cardiologist veriﬁed all probable and possible cases, and
all cases in which the two physicians could not reach consensus. If
the cardiologist disagreed with the research physicians, the cardio-
logist’s judgement was considered decisive. The research physicians
and the cardiologist based their decisions on the same data. Only
deﬁnite and probable cases were included in the analyses.
Statistical analysis
To compare the baseline characteristics of the random subcohort to
the remainder of the Rotterdam Study, we used a x
2 test for dichot-
omous variables, a t-test for continuous variables, and a Mann–
Whitney test for C-reactive protein, because its distribution was
skewed. We used ANCOVA to display age- and sex-adjusted baseline
characteristics of the participants in different Lp-PLA2 activity
quartiles. We log-transformed C-reactive protein because of its
skewed distribution and we computed the geometric mean. We
computed the standard deviation and interquartile range from the
standard error. To compute P-value for trend for the baseline
characteristics, we used logistic regression for dichotomous vari-
ables and linear regression for continuous variables. In both cases,
continuous plasma values of Lp-PLA2 activity were used as the inde-
pendent variable.
We used Cox proportional hazards models to evaluate the associ-
ation of Lp-PLA2 activity with risk of heart failure. Subjects were
censored at the time of occurrence of heart failure, death, or at
Lp-PLA2 activity and heart failure 2347
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 the end of the study period. Furthermore, we censored subjects at
the time of occurrence of myocardial infarction, PTCA, or CABG
if these took place before the occurrence of heart failure, to
account for coronary heart disease. The proportional hazards
assumption was tested by drawing log minus log plots of the survival
function, which conﬁrmed that the assumption was met. In model
1, we adjusted for age and sex. Lp-PLA2 is tightly associated with
lipoproteins; in humans, it is predominantly located on LDL and,
to a smaller extent, on HDL. Because these factors were most
likely to be confounders, in model 2, we additionally adjusted for
non-HDL cholesterol and HDL cholesterol. In model 3, we addition-
ally adjusted for body mass index, systolic blood pressure, diastolic
blood pressure, hypertension, smoking status, diabetes mellitus,
and C-reactive protein. First, we entered the continuous plasma
values of Lp-PLA2 activity into the models to obtain the hazard
ratio for heart failure per unit increase in Lp-PLA2 activity. By
this means, we also obtained the P-value for trend. Second, to
allow for the demonstration of a possibly non-linear association,
we made quartiles of Lp-PLA2 activity with cutpoints 35.9, 42.9,
and 50.8 nmol/min per mL plasma and used the lowest quartile as
the reference category.
To compare survival time until the occurrence of heart failure in
the quartiles of Lp-PLA2 activity, C-reactive protein, and non-HDL
cholesterol, we made event-free survival curves adjusted for age
and sex.
We conducted a subgroup analysis to compare the association
between Lp-PLA2 activity and heart failure in subjects with a
non-HDL cholesterol level below and above the median (cutpoint
5.20 mmol/L). Lp-PLA2 was dichotomized in this analysis, using
the median as a cutoff point (42.9 nmol/min per mL plasma). We
adjusted for age, sex, HDL cholesterol, body mass index, systolic
blood pressure, diastolic blood pressure, hypertension, smoking
status, diabetes mellitus, and C-reactive protein. We did a similar
subgroup analysis in the strata of C-reactive protein (cutpoint
1.79 mg/L), adjusting for non-HDL cholesterol instead of C-reactive
protein in the Cox proportional hazard model.
To test for interaction between Lp-PLA2 activity and non-HDL
cholesterol and C-reactive protein, we entered interaction terms
into the model, using continuous values of Lp-PLA2 activity
instead of quartiles of Lp-PLA2 activity and using non-HDL choles-
terol and C-reactive protein as continuous variables. In this analysis,
we adjusted for age and sex.
Values for covariates were missing in ,3%, except for C-reactive
protein(6%missingvalues).Weusedsingleimputationbasedonexpec-
tation maximization to handle missing values.
Results
The mean follow-up time until censoring was 6.7 years (SD
2.3 years). During follow-up, 113 incident heart failure
cases occurred. Of these cases, 19 were preceded by coro-
nary heart disease. Therefore, 94 incident cases of heart
failure were left for analysis.
Table 1 shows the baseline characteristics of the total
random cohort and the remainder of the Rotterdam Study.
The characteristics of the random cohort were similar to
the remainder of the Rotterdam Study, except for age,
systolic blood pressure, and hypertension. Subjects in the
random cohort were slightly younger (69.1 vs. 71.1 years),
had a lower systolic blood pressure (138.2 vs.
139.9 mmHg.), and had a lower prevalence of hypertension
(33.1 vs. 37.1%). Table 2 shows the baseline characteristics
of participants in different quartiles of Lp-PLA2 activity
adjusted for age and sex (when appropriate) and the
P-value for trend. In all linear regression models we used,
the residuals were normally distributed with a constant
variance. Quartiles with a higher Lp-PLA2 activity contained
a higher percentage of men and hypertensive participants.
They had a signiﬁcantly higher body mass index, systolic
blood pressure, non-HDL cholesterol, and C-reactive
protein. HDL cholesterol was lower in participants within
higher quartiles of Lp-PLA2 activity.
Lp-PLA2 activity was associated with risk of heart failure
(Table 3). After adjustment for age and sex, the hazard
ratio for heart failure per unit increase in Lp-PLA2 activity
was 1.02 [95% conﬁdence interval (CI) 1.00–1.03],
P ¼ 0.026. After additional adjustment for non-HDL choles-
terol and HDL cholesterol, this was 1.02 (95% CI
1.00–1.04), P ¼ 0.024, and after additional adjustment for
known cardiovascular risk factors, 1.03 (95% CI 1.01–1.05),
P ¼ 0.011. Participants in the second, third, and fourth
quartiles of Lp-PLA2 activity had a hazard ratio of 0.99
(95% CI 0.52–1.86), 1.27 (95% CI 0.68–2.40), and 1.93 (95%
CI 1.09–3.42), respectively, for heart failure, using the
ﬁrst quartile of Lp-PLA2 activity as the reference category
and adjusting for age and sex. Using model 2, this was
1.01 (95% CI 0.53–0.92), 1.34 (95% CI 0.69–2.60), and 2.16
Table 1 Baseline characteristics of the study population
Variable Random cohort (n ¼ 1820) Remainder Rotterdam Study (n ¼ 6163) P-value
Age, years 69.1+ 9.1 71.1+ 9.9 ,0.01
Men, % 38.3 39.1 0.55
Body mass index, kg/m
2 26.2+ 3.7 26.3+ 3.8 0.3
Systolic blood pressure, mmHg 138.2+ 22.3 139.9+ 22.4 ,0.01
Diastolic blood pressure, mmHg 73.3+ 11.2 73.8+ 11.8 0.12
Hypertension, % 33.1 37.1 ,0.01
Non-HDL cholesterol, mmol/L 5.30 +1.24 5.24+ 1.23 0.1
HDL cholesterol, mmol/L 1.35 +0.38 1.34+ 0.37 0.38
Diabetes mellitus, % 9.8 10.7 0.31
Smokers, %
Current 23 22.5 0.68
Former 41.7 40.4 0.34
Never 35.3 37 0.18
C-reactive protein, mg/L 1.78 (0.90–3.59)
a 1.93 (0.92–3.71)
a 0.07
Continuous variables are expressed as mean+ standard deviation. Categorical variables are expressed as percentage.
aMedian and interquartile range because of skewed distribution.
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 (95% CI 1.13–4.11), respectively. Using model 3, this further
increased to 1.06 (95% CI 0.55–2.04), 1.43 (95% CI
0.73–2.81), and 2.33 (95% CI 1.21–4.49), respectively.
The event-free survival curve according to quartiles of
Lp-PLA2 activity shows that the survival time until the
occurrence of heart failure was higher in the lowest quartile
than in the highest quartile (Figure 1). The curve also illus-
trates that the difference in risk between quartiles 1 and 4 is
rather consistent over time. Figures 2 and 3 show the event-
free survival curve of C-reactive protein and non-HDL
cholesterol, respectively. Although C-reactive protein was
signiﬁcantly related to the event-free survival time, no
clear association was found for non-HDL cholesterol.
Figure 4 shows the results of our subgroup analyses. The
hazard ratios for heart failure associated with Lp-PLA2
activity for the subgroups below and above the median of
non-HDL cholesterol level were 1.89 (95% CI 1.05–3.39)
and 1.77 (95% CI 0.83–3.79), respectively. The hazard ratio
was somewhat larger in subjects with a non-HDL cholesterol
below the median, but no signiﬁcant interaction was found
between Lp-PLA2 activity and non-HDL cholesterol
(P-value for interaction ¼ 0.817) in relation to risk of
heart failure. The hazard ratio for the subjects with a
C-reactive protein below the median was 3.83 (95% CI
1.64–8.93), which was higher than the hazard ratio for the
subjects with C-reactive protein above the median,
namely 1.26 (95% CI 0.71–2.23). However, the interaction
term for Lp-PLA2 activity and C-reactive protein was not
signiﬁcant (P-value for interaction ¼ 0.364).
Discussion
In the present population-based cohort study, Lp-PLA2
activity was an independent predictor of heart failure. The
association persisted after we adjusted for known cardiovas-
cular risk factors and C-reactive protein. A signiﬁcant trend
was seen, and subjects in the highest quartile had no less
than a doubled risk of developing heart failure compared
with subjects in the lowest quartile, even though we
excluded subjects with prevalent coronary heart disease at
baseline and censored subjects with incident coronary
heart disease during follow-up. This suggests that the associ-
ation found between Lp-PLA2 activity and heart failure is
independent of coronary heart disease.
To our knowledge, this is the ﬁrst study performed on the
association between Lp-PLA2 and risk of heart failure. The
present study is a population-based prospective cohort
study, which guards our study from selection and recall
bias. Strengths of our study include the ability to account
for possible confounding by incorporating established cardio-
vascular risk factors into the statistical models. Finally, we
were able to account for prevalent and incident coronary
heart disease in our analysis.
The pathophysiology of heart failure is complex. Heart
failure was once considered to be merely a cardiocirculatory
impairment, but now it is known that the neuroendocrine
system is involved. Evidence is accumulating that inﬂam-
mation also plays a direct role in the pathophysiology of
heart failure. In former studies, several inﬂammatory
markers, such as interleukin-6,
1 tumour necrosis factor-a,
2
and C-reactive protein,
3 have been associated with inci-
dence of heart failure. Inﬂammatory mediators have been
found to affect left ventricular remodelling, left ventricular
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 dysfunction, pulmonary oedema, fetal gene expression, and
cardiomyopathy.
4,5 Finally, a correlation has been found
between high blood levels of inﬂammatory markers and
poorer prognosis in heart failure patients.
6
In the Atherosclerosis Risk in Communities study, an
association between Lp-PLA2 and incident coronary heart
disease was present after adjustment for age, sex, and
race. After further adjustments for cardiovascular risk
factors, the association was only present in subjects with a
low LDL cholesterol.
9 Our subgroup analysis showed that
the association found between Lp-PLA2 activity and heart
failure is present in subjects with a non-HDL cholesterol
level below the median as well as in subjects with a
non-HDL cholesterol level above the median, although in
the latter group, the association lacked signiﬁcance. The
association between Lp-PLA2 and heart failure was much
stronger in subjects with a C-reactive protein level below
the median than in subjects with a C-reactive protein
level above the median. We have no explanation for this
difference in risk estimates. The interaction between
Lp-PLA2 and C-reactive protein was not signiﬁcant, so the
difference may be due to chance.
Figure 3 Survival time until the occurrence of heart failure according to
quartiles of non-HDL cholesterol, adjusted for age and sex.
Figure 1 Survival time until the occurrence of heart failure according to
quartiles of Lp-PLA2, adjusted for age and sex.
Figure 2 Survival time until the occurrence of heart failure according to
quartiles of C-reactive protein, adjusted for age and sex.
Table 3 Hazard ratios for heart failure according to quartiles of Lp-PLA2 activity
Lp-PLA2 (nmol/min per mL) Cases/subjects Hazard ratio (95% CI)
Model 1 Model 2 Model 3
Unit increase 94/1590 1.02 (1.00–1.03) 1.02 (1.00–1.04) 1.03 (1.01–1.05)
P-value for trend 0.026 0.024 0.011
Quartile 1 18/397 1 (reference) 1 (reference) 1 (reference)
Quartile 2 20/398 0.99 (0.52–1.86) 1.01 (0.53–1.92) 1.06 (0.55–2.04)
Quartile 3 21/398 1.27 (0.68–2.40) 1.34 (0.69–2.60) 1.43 (0.73–2.81)
Quartile 4 35/397 1.93 (1.09–3.42) 2.16 (1.13–4.11) 2.33 (1.21–4.49)
Model 1 adjusted for age and sex; model 2 adjusted for age, sex, non-HDL cholesterol, and HDL cholesterol; model 3 adjusted for age, sex,
non-HDL cholesterol, HDL cholesterol, body mass index, systolic blood pressure, diastolic blood pressure, hypertension, diabetes mellitus,
smoking status, and C-reactive protein.
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 Several studies have investigated the association between
LDL cholesterol and heart failure.
23–25 Although the
Framingham Study found a positive relation,
26 subsequent
studies were not able to conﬁrm this. In our study, we also
failed to ﬁnd a clear relation between non-HDL cholesterol
and risk of heart failure. Lp-PLA2 is an enzyme bound to
LDL cholesterol and therefore Lp-PLA2 activity is highly cor-
related with LDL cholesterol levels. In the present study, we
found that the association of Lp-PLA2 with heart failure was
independent of non-HDL cholesterol. We used non-HDL
cholesterol for adjustment, since no measurements of LDL
cholesterol were available. Because of the high correlation
between LDL cholesterol and non-HDL cholesterol in a
random sample of our cohort (r ¼ 0.97, P , 0.001), we
believe that residual confounding by LDL cholesterol
cannot explain our results.
11
In conclusion, our ﬁndings suggest that Lp-PLA2 activity
is independently associated with risk of heart failure.
Our study provides further evidence that inﬂammation is
involved in the aetiology of heart failure.
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